Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3GU7K)

Drug Name
Pyridic ketone derivative 1 Drug Info
Synonyms PMID28594589-Compound-TABLE3c3
Cross-matching ID
PubChem CID
118041703
TTD Drug ID
DM3GU7K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting ERK activator kinase 1 (MEK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selumetinib DMC7W6R Neurofibromatosis type 1 LD2D.10 Phase 3 [2]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [3]
RDEA-436 DM0ILRU Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [4]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [5]
DEBROMOHYMENIALDISINE DMDLER8 Discovery agent N.A. Investigative [6]
REVERSINE DMWDNOK Discovery agent N.A. Investigative [7]
OROIDIN DMA2DQT Discovery agent N.A. Investigative [6]
PD98059 DMZC90M Cardiac arrest MC82 Investigative [8]
4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide DMDM9UV Discovery agent N.A. Investigative [6]
5-phenylamino-4-cyano-3-hydroxy-isothiazole DMX6R0H Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting ERK activator kinase 2 (MEK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selumetinib DMC7W6R Neurofibromatosis type 1 LD2D.10 Phase 3 [2]
RDEA-436 DM0ILRU Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [4]
PD98059 DMZC90M Cardiac arrest MC82 Investigative [8]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ERK activator kinase 1 (MEK1) TTIDAPM MP2K1_HUMAN Inhibitor [1]
ERK activator kinase 2 (MEK2) TTTW2NY MP2K2_HUMAN Inhibitor [1]

References

1 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4 Clinical pipeline report, company report or official report of MedKoo Biosciences.
5 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
6 Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
7 Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
8 The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.
9 Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80.